Latest news


PCI Biotech and Ultimovacs initiates preclinical research collaboration

Posted on Jan 27, 2016

Oslo, 27 January 2016 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and Ultimovacs, a pharmaceutical company developing novel immunotherapy against cancer, today announced that they are initiating a preclinical research collaboration. The purpose of the collaboration is to utilise the companies’ complementary scientific platforms to explore potential synergies. The partnership is governed […]

Dose escalation in the bile duct cancer study completed with promising early signs of efficacy

Posted on Jan 22, 2016

Oslo, 22 January 2016 – PCI Biotech (PCIB) reported today that the treatment evaluation of the fourth dose cohort in the Phase I/II study of fimaporfin (Amphinex®) in patients with inoperable bile duct cancer has been completed.  The   Cohort   Review   Committee   (CRC)   of clinical experts and company representatives has recommended that the study progress into […]

PCI Biotech to present at DNB Health Care Conference 2015

Posted on Dec 15, 2015

Lysaker, 15 December 2015 – PCI Biotech will present at DNB Health Care Conference today 12:45 local time at DNB Head Office, Oslo, Norway. The company will be represented by Dr. Per Walday, CEO. 1512 PCIB DNB Health Care Conf About PCI Biotech PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and […]